Sang-Sun Joung

Title: Inventor Sang-Sun Joung: Innovator in HMG-CoA Reductase Inhibitors

Introduction

Sang-Sun Joung is an accomplished inventor based in Hwaseong-si, South Korea. He holds a significant patent in the field of medicinal chemistry, particularly concerning HMG-CoA reductase inhibitors. His work contributes to the development of important pharmaceutical compounds that play a vital role in cholesterol management and cardiovascular health.

Latest Patents

Sang-Sun Joung is credited with a patent titled "Process for the preparation of HMG-COA reductase inhibitors and intermediates thereof." This invention presents an improved method for synthesizing HMG-CoA reductase inhibitors, including rosuvastatin calcium, fluvastatin sodium, and pitavastatin calcium. The process utilizes a novel amide-bond-containing compound with an R—N—O—R moiety as a key intermediate, allowing these compounds to be prepared under mild conditions. The invention also includes details about the novel compound and the preparation process for useful intermediates.

Career Highlights

Joung is associated with Yuhan Corporation, a prominent player in the pharmaceutical industry. His work focuses on developing safer and more effective methods for producing compounds that contribute to better healthcare solutions. With one patent under his name, he has demonstrated a commitment to innovation in drug formulation and synthesis.

Collaborations

During his time at Yuhan Corporation, Sang-Sun Joung has collaborated with talented coworkers, including Hyun Ju and Hyun-Jik Yi. This teamwork reflects the collaborative nature of research and development within the organization, fostering an environment where innovative ideas can thrive.

Conclusion

Sang-Sun Joung's contributions to the field of pharmaceutical sciences through his patent on HMG-CoA reductase inhibitors exemplify the impact of innovative thinking in healthcare. As he continues to work with Yuhan Corporation, his pursuit of advancements in drug synthesis is likely to benefit many and enhance the pharmaceutical landscape.